TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Misoprostol Versus Uterine Striating by Bladder Filling for Pain Relief During Office Hysteroscopy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Menopausal patients who have an indication for office hysteroscopy~Exclusion Criteria:~* Nulliparous patients, patients with cervical pathology and previous cesarean section or cervical surgery.

- Gender: FEMALE
- Minimum Age: 40 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Misoprostol (Type: ACTIVE_COMPARATOR): Misoprostol (400µg) is administered vaginally 12 hours before office hysteroscopy
- bladder Filling (Type: ACTIVE_COMPARATOR): Uterine straightening by bladder filling before office hysteroscopy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Exercise Therapy Program in Ankylosing Spondylitis Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Ankylosing spondylitis patient~* Basdai index lower than 4~* Physical inactive~* Functional class I to III~Exclusion Criteria:~* Fibromyalgia~* Cardiovascular disease~* Pain Visual Analogue Scale (VAS) over 8

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ankylosing spondylitis control (Type: NO_INTERVENTION): control group
- mobility exercise (Type: EXPERIMENTAL): mobility exercises
- mobility and elastic resistance exercise (Type: EXPERIMENTAL): AS patients was submitted to a program mobility exercise plus elastic resistance exercises

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Role of Midodrine and Tolvaptan in Patients With Cirrhosis With Refractory or Recurrent Ascites

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:60 consecutive patients with cirrhosis and refractory or recurrent ascites with stable renal function ( creatinine level \<1.5mg/dl for at least 7 days ).~Exclusion Criteria:~* Presence of gastrointestinal bleeding, HRS, hepatic encephalopathy of grade 2 or higher or infection within 1 month preceding the study or during the study, presence of diabetes, intrinsic renal or cardiovascular disease or arterial hypertension on history and physical examination, abnormal urine analysis, chest radiograph or electrocardiogram, presence of hepatocellular carcinoma or portal vein thrombosis or treatment with drugs with known effects on systemic and renal hemodynamics within 7 days of inclusion .

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Standard medical therapy (Type: ACTIVE_COMPARATOR): Standard Medical therapy (n-15) with100 to 400mg spironolactone and/or 40 to 160mg furosemide.
- Midodrine group (Type: ACTIVE_COMPARATOR): Standard medical therapy (n-15) with Midodrine 7.5 mg thrice a day
- Tolvaptan group (Type: ACTIVE_COMPARATOR): Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day
- Tolvaptan plus midodrine arm (Type: EXPERIMENTAL): Standard medical therapy (n-15) with Tolvaptan 15 mg twice a day and Midodrine 7.5 mg thrice a day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 99Tc-MDP in Postmenopausal Women With Differentiated Thyroid Cancer and Osteoporosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~(1) They were pathologically diagnosed with DTC including papillary or follicular carcinoma. (2) They received a near total thyroidectomy and radioiodine treatment. (3) TSH suppression should be at least one year before the study. (4) Bone mineral density (BMD) in lumbar spine and/or hip was tested by Dual-energy X-ray absorptiometry (DXA) at baseline, 6 month (m) and/or 12m follow up. 5) The diagnosis of osteoporosis was T-score ≤-2.5 SD at the lumbar spine, or hip.~Exclusion Criteria:~1. patients having medications for osteoporosis before TSH suppression treatment;~2. secondary osteoporosis ;~3. severe liver or kidney disease;~4. myelosuppression;~5. digestive disease;~6. long term use of immunosuppressive agent, estrogen or estrogen receptor modulators. This study was approved by the Institutional Review Board of Hospital Research Ethics. All the patients were fully acquainted with their treatment and consented to participate in the clinical trial.

- Gender: FEMALE
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 99Tc-MDP (Type: EXPERIMENTAL): 15mg 99Tc-MDP were intravenously administered twice a week for 10 weeks, then once a week for 8 weeks, every two weeks for 22 weeks and monthly for another 3m.
- Fosamax (Type: ACTIVE_COMPARATOR): 70mg po every week for 12 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female between the ages of 18 and 70 years diagnosed with type 2 diabetes.~* Body mass index (BMI) between 18 kg/m2 and 37 kg/m2 (inclusive).~* HbA1c levels between 6.5 and 9.5 (inclusive) where the upper limit of normal for the HbA1c assay is 6.4% or HbA1c levels between 6.2 and 9.5% (inclusive) where the upper limit of normal for the HbA1c assay is 6.1%.~* Fasting plasma glucose levels between 126 and 270 mg/dL (7 - 15 mmol/L, inclusive) while on diabetic medications.~* Treatment naïve subjects with HbA1c between 6.5 and 9.5 and fasting plasma glucose between 126 and 270 mg/dL (7 - 15 mmol/L).~* If taking drugs for diabetes, must be medically able and willing to discontinue diabetic medications for the duration of the study.~* Female subjects must be surgically sterilized or postmenopausal.~Exclusion Criteria:~* Type 1 diabetes or diabetes treated with insulin injection.~* Insulin therapy or oral antidiabetic medication other than metformin, sitagliptin, saxagliptin, a sulfonylurea or combination of these.~* Sitting blood pressure above 150/95 mmHg on two evaluations at least 10 minutes apart at screening.~* Positive results on screen for drugs of abuse.~* Previous treatment with an investigational drug within 30 days or 7 half-lives, whichever is longer.~* Previous treatment with EGT0001474 or EGT0001442.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- EGT0001442 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Human Epidermal Growth Receptor (HER2) Status Evaluation in Breast Cancer Pathology Samples

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Samples that fulfill all of the criteria will be evaluated for the study.~* Samples of women aged greater than or equal to (\>/=) 18 and less than (\<) 75 years~* Tumor samples already diagnosed based on the IHC score of 0 to +3~* Samples of primary lesions excluding lymph nodes~* 10 percent (%) neutral buffered formalin-fixed and paraffin embedded tissue samples~Exclusion Criteria:~Samples that fulfill any of the criteria below will not be included in the study.~* Non-invasive ductal carcinoma (NOS) samples~* Tru-cut biopsies~* Non-breast cancer pathological samples

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Breast Cancer Pathology Samples (Type: None): Breast cancer pathology samples were evaluated for a period of 70 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of AG-013736 In Patients With 131I-Refractory Thyroid Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Radioiodine-refractory metastatic or unresectable locally-advanced thyroid cancer~* At least 1 measurable target lesion, as defined by RECIST~Exclusion Criteria:~* Thyroid lymphoma~* Previous treatment with anti-angiogenesis agents~* No myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, cerebrovascular accident or transient ischemic attack, deep vein thrombosis or pulmonary embolism within 12 months prior.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Rivaroxaban for the Prevention of Venous Thromboembolism in Asian Patients With Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients ≥ 20 years old and active cancer and newly-diagnosed, symptomatic or incidental proximal lower extremity DVT, PE or both~* will have a life expectancy \> 3 months~* will be treated with anticoagulation therapy for at least 3 months.~Exclusion Criteria:~* (1) Isolated asymptomatic distal DVT~* (2) Intra-abdominal venous thrombosis or vascular access-induced thrombosis~* (3) Hemodynamically unstable PE, indicating systolic blood pressure \<90 mmHg~* (4)Eastern Cooperative Oncology Group (ECOG) performance status score of 3 or 4~* (5) History of total gastrectomy~* (6) Overt brain metastasis. Patients who have controlled brain metastasis without need of glucocorticoid are eligible~* (7) History of recent major or clinically relevant bleeding within the previous 4 weeks~* (8) Conditions associated with a high risk of serious bleeding (active peptic ulcer or recent neurosurgery)~* (9) Other serious illness or medical conditions (illnesses requiring chronic anticoagulation therapy, unstable cardiac disease despite treatment, myocardial infarction within 3 months prior to study entry, significant neurologic or psychiatric diseases including dementia or seizure, active uncontrolled infection, other serious medical conditions)~* (10)Inadequate renal function; creatinine clearance \< 30 ml/min~* (11) Inadequate hepatic function: alanine aminotransferase \> 3 times the upper limit of normal (ULN) (if liver metastasis, alanine aminotransferase \> 5 times the ULN or total bilirubin \>2 times the ULN (if liver metastasis, total bilirubin \>3 times the ULN)~* (12) Baseline platelet count \< 75,000 per cubic millimeter or Hb \< 8g/dL~* (13) Plan of treatment with bevacizumab or other anti-cancer drugs known to increase the bleeding risk~* (14) Women of childbearing potential who are unwilling or unable to use an acceptable method of contraception to avoid pregnancy for the entire study period, who are using a prohibited contraceptive method, or who are pregnant or breastfeeding~* (15) Patients requiring strong cytochrome P450 3A4 (CYP3A4) inducers (rifampin, phenobarbital) or strong CYP3A4 inhibitors (HIV protease inhibitor, systemic ketoconazole) treatments~* (16) Patients with inferior vena cava filter placement or underwent catheter-directed thrombolysis or stent placement for the treatment of index VTE

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- oral rivaroxaban in cancer-associated VTE (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pilot Study of the Feasibility and Efficacy of Working Memory Training in Children With Cochlear Implants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* age 7-16 years at the time of study enrollment,~* profound bilateral hearing loss (\> 90 dB HL in the better hearing ear),~* implantation prior to age 3 years,~* use of multichannel CI's,~* a monolingual English home environment,~* enrollment in an aural rehabilitative program that encourages the development of speaking and listening skills,~* educational environment that uses oral or total communication (TC) strategies,~* sufficient speech perception and language competence to complete basic word and sentence repetition tasks,~* no significant developmental delay or neurological condition that, in the opinion of the investigators, would interfere markedly with cognitive functioning,~* Windows-based PC at home capable of running Cogmed working memory training software,~* mild or greater deficit in working memory, as shown by either (a) a Behavior Rating Inventory of Executive Function (BRIEF) working memory T-score of 50 or higher or (b) a Digit Span scaled score of 10 or lower. Subjects will be discontinued if during the study they have any new or changed intervention (including medication) that involves working memory, attention, concentration, or executive functioning.~Exclusion Criteria:~* Under 7 years or over 16 years of age at time of study entry~* Implantation after age 3 years~* Bilingual or non-English-speaking home environment~* Primary use of American Sign Language (ASL)

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Cogmed Working Memory Training (Type: EXPERIMENTAL): Cogmed Working Memory Training Program

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Nafamostat Mesilate in Prolonging Filter Patency With Patients on Continuous Renal Replacement Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients who have at least one of the hemorrhagic tendencies of following conditions and needs CRRT hemodynamically;~  1. Platelet count \< 100,000~ 2. aPTT \> 60 sec~ 3. PT-INR \> 2.0~ 4. active hemorrhage~ 5. surgery within 48 hours~ 6. cerebral hemorrhage within 3 months or history of major bleeding~ 7. septic shock or DIC.~Exclusion Criteria:~* pregnancy, breast feeding, possibility of pregnancy,~* allergy to nafamostat mesilate,~* other conditions that physician consider unfit for candidate.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- M100 (Type: ACTIVE_COMPARATOR): heparin free CRRT group
- HF1000 (Type: EXPERIMENTAL): CRRT with nafamostat mesilate anticoagulation group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ex-vivo Expanded γδ T-lymphocytes (OmnImmune®) in Patients With Acute Myeloid Leukaemia (AML)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. History of acute myeloid leukaemia (initially diagnosed by presence of 20% or more blast cells with myeloid or monocytic differentiation confirmed by flow cytometry in peripheral blood or bone marrow)~2. Relapsed or refractory AML~   1. AML relapse after intensive chemotherapy OR~  2. AML relapse after allogeneic HCT OR~  3. AML progression on low intensity therapy (low dose cytarabine, 5-azacytidine or decitabine) OR~  4. No response to at least 4 cycles of low intensity therapy~  5. AML refractory to 2 cycles of induction chemotherapy~3. Presence of \> 5% of blasts in bone marrow or peripheral blood smear~4. Patient not eligible for or does not consent to high dose salvage chemotherapy and/or allogeneic Haematopoietic Cell Transplantation (HCT)~5. Considered suitable for lymphodepleting chemotherapy~6. Age 18 years up to the age of 70 (≤ 70)~7. Life expectancy of at least 3 months~8. Karnofsky performance status ≥ 50%~9. Available related HLA-haploidentical or HLA-matched donor~10. Ability to be off systemic prednisone and other immunosuppressive drugs for at least 3 days prior to γδ T cells product infusion. Maintenance replacement steroid is allowed.~11. Patient able to understand and sign written informed consent~Exclusion Criteria:~1. Uncontrolled infections~2. Renal insufficiency: creatinine \> 180 μmol/L or on dialysis~3. Heart failure: EF \< 40%~4. Respiratory insufficiency: oxygen therapy required at inclusion in the study~5. Significant liver impairment: bilirubin \> 50 μmol/L, AST or ALT \> 4 times normal upper limit~6. Treatment with bisphosphonates (2 months before start)~7. Active autoimmune disease or GvHD~8. Pregnant or breastfeeding~9. Patient of fertile age not using two-barrier method of birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Treatment Arm (Type: EXPERIMENTAL): After inclusion, patients will receive conditioning chemotherapy consisting of non-investigational medicinal products (non-IMPs): fludarabine 25 mg/m2 from day -6 until day -2 (inclusive) and cyclophosphamide 500 mg/m2 on days -6 and -5.~Subsequently, patients in will be dosed with investigational medicinal product (IMP) OmnImmune® on day 0.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Open Label Study Assessing Effectiveness Of Amlodipine/Atorvastatin In Subjects With Hypertension and Dyslipidaemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who are above target LDL-C and BP who are eligible for treatment~Exclusion Criteria:~* High liver enzymes

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Trial on Growth Hormone Deficiency in Adults (GHDA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects who completed GHLiquid-1518.~* If the subject has a history of treatment for a tumor of pituitary or peripheral site, two years or more have to be passed since completion of surgery, radiotherapy or other treatment, and recurrence of the underlying disease to be excluded.~* Appropriate replacement therapy has been administered for more than 24 weeks for the treatment of other pituitary hormone deficiencies.~Exclusion Criteria:~* Subject with a history of acromegaly.~* Subject with diabetes mellitus.~* Subject suffering from malignancy.~* Several medical conditions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Recovery After Laparoscopic Hysterectomy With Deep Neuromuscular Blockade and Low Intra-abdominal Pressure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Elective laparoscopic hysterectomy (total/subtotal)~* Can read and understand Danish~* Informed consent~Exclusion Criteria:~* BMI \> 30 kg/cm2~* Known allergy to medications that are included in the project~* Severe renal disease, defined by S-creatinine \> 0,200 mmol/L, GFR \< 30ml/min or hemodialysis)~* Neuromuscular disease that may interfere with neuromuscular data~* Lactating~* Impaired liver function~* Indication for rapid sequence induction (esophageal reflux/ hiatus hernia/other cause)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Deep neuromuscular blockade (Type: ACTIVE_COMPARATOR): Drug: Rocuronium Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h Other Name: Esmeron
- Moderate neuromuscular blockade (Type: PLACEBO_COMPARATOR): Drug: Rocuronium Intravenous use: 0,3 mg/kg followed by NaCl-infusion Other Name: Esmeron

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete